Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative
Thompson K, Kalkowska D, Badizadegan K
Gates Open Research, 2022; 6(5). doi:10.12688/gatesopenres.13524.1. [version 1; awaiting peer review]
Health economic analyses of secondary vaccine effects: a systematic review and policy insights
Thompson KM, Badizadegan K
Expert Rev Vaccines, 2022:1-16. doi:10.1080/14760584.2022.2017287.
An updated economic analysis of the global polio eradication initiative
Thompson KM, Kalkowska DA
Risk Anal, 2021; 41(2):393-406. doi:10.1111/risa.13665.
Health and economic outcomes associated with polio vaccine policy options: 2019–2029
Kalkowska DA, Thompson KM
Risk Anal, 2021; 41(2):364-375. doi:https://doi.org/10.1111/risa.13664.
No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]
Thompson KM, Kalkowska DA, Badizadegan K
Risk Anal, 2021; 41(2):389-392. doi:10.1111/risa.13671.
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States
Thompson KM, Kalkowska DA, Badizadegan K
Risk Anal, 2021; 41(2):376-386. doi:10.1111/risa.13614.
Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America
Badizadegan K, Vanlandingham DM, Hampton W, Thompson KM
BMC Health Serv Res, 2020; 20(1):962. doi:10.1186/s12913-020-05815-0.
Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019
Thompson KM, Orenstein WA, Hinman AR
Vaccine, 2020; 38(9):2136-2143. doi:https://doi.org/10.1016/j.vaccine.2020.01.042.
An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches
Thompson KM, Orenstein WA, Hinman AR
Vaccine, 2020. doi:10.1016/j.vaccine.2020.04.044.
Valuing health outcomes: developing better defaults based on health opportunity costs
Ochalek J, Claxton K, Lomas J, Thompson KM
Expert Rev Pharmacoecon Outcomes Res, 2020:1-8. doi:10.1080/14737167.2020.1812387.
Potential Future Use, Costs, and Value of Poliovirus Vaccines
Thompson KM, Kalkowska DA
Risk Anal, 2021; 41(2):349-363. doi:10.1111/risa.13557.
Modeling pathology workload and complexity to manage risks and improve patient quality and safety
Vanlandingham DM, Hampton W, Thompson KM, Badizadegan K
Risk Anal, 2020; 40(2):421-434. doi:10.1111/risa.13393.
Characterising the costs of the global polio laboratory network: a survey-based analysis
Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM
BMJ Open, 2019; 9(1):e023290. doi:10.1136/bmjopen-2018-023290.
Radiofrequency Interference in the Clinical Laboratory
Badizadegan ND, Greenberg S, Lawrence H, Badizadegan K
Am J Clin Pathol, 2019; 151(5):522-528. doi:10.1093/ajcp/aqy174.
Systematic review of the incremental costs of interventions that increase immunization coverage
Ozawa S, Yemeke TT, Thompson KM
Vaccine, 2018; 36(25):3641-3649. doi:10.1016/j.vaccine.2018.05.030.
Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
Duintjer Tebbens RJ, Thompson KM
Epidemiol Infect, 2017; 145(2):217-226. doi:10.1017/S0950268816002302.
Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use
Duintjer Tebbens RJ, Thompson KM
MDM Policy Pract, 2017; 2(1):2381468317697002. doi:10.1177/2381468317697002.
Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
Duintjer Tebbens RJ, Thompson KM
Vaccine, 2017; 35(31):3823-3833. doi:10.1016/j.vaccine.2017.05.090.
Systematic review of health economic analyses of measles and rubella immunization interventions
Thompson KM, Odahowski CL
Risk Anal, 2016; 36(7):1297-314. doi:10.1111/risa.12331.
The costs and valuation of health impacts of measles and rubella risk management policies
Thompson KM, Odahowski CL
Risk Anal, 2016; 36(7):1357-82. doi:10.1111/risa.12459.
The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management
Duintjer Tebbens RJ, Thompson KM
Future Microbiol, 2016; 11:1549-1561. doi:10.2217/fmb-2016-0126.
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
Thompson KM, Duintjer Tebbens RJ
BMC Infect Dis, 2015; 15:374. doi:10.1186/s12879-015-1113-7.
The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
Thompson KM, Duintjer Tebbens RJ
BMC Infect Dis, 2015; 15:376. doi:10.1186/s12879-015-1116-4.
An economic analysis of poliovirus risk management policy options for 2013-2052
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM
BMC Infect Dis, 2015; 15:389. doi:10.1186/s12879-015-1112-8.
Medical student knowledge, attitudes, and practices regarding immunization
Berera D, Thompson KM
J Vaccines Vaccin, 2015; 6(1):1000268. doi:10.4172/2157-7560.1000268.
Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention
Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL
Vaccine, 2013; 31 Suppl 2:B149-56. doi:10.1016/j.vaccine.2012.11.091.
Pediatric traumatic brain injury and radiation risks: a clinical decision analysis
Hennelly KE, Mannix R, Nigrovic LE, Lee LK, Thompson KM, Monuteaux MC, Proctor M, Schutzman S
J Pediatr, 2013; 162(2):392-7. doi:10.1016/j.jpeds.2012.07.018.
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation
Thompson KM, Duintjer Tebbens RJ
Expert Rev Vaccines, 2012; 11(4):449-59. doi:10.1586/erv.11.195.
Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases
Thompson KM
ICU Management, 2012; 12(4):9-11. doi:N/A.
Research priorities for global measles and rubella control and eradication
Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM
Vaccine, 2012; 30(32):4709-16. doi:10.1016/j.vaccine.2012.04.058.
Group report: developing an eradication investment case
Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker D
In Disease Eradication in the 21st Century: Implications for Global Health, S.L. Cochi and W.R. Dowdle, Editors. 2011, MIT Press: Cambridge, MA. p. 133-148.
Economic evaluation of the benefits and costs of disease elimination and eradication initiatives
Thompson KM, Duintjer Tebbens RJ
In Disease Eradication in the 21st Century: Implications for Global Health, S.L. Cochi and W.R. Dowdle, Editors. 2011, MIT Press: Cambridge, MA. p. 115-130.
Value of information in nonfocal colonic biopsies
Badizadegan K, Thompson KM
J Pediatr Gastroenterol Nutr, 2011; 53(6):679-83. doi:10.1097/MPG.0b013e31822862d9.
Economic analysis of the global polio eradication initiative
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM
Vaccine, 2010; 29(2):334-43. doi:10.1016/j.vaccine.2010.10.026.
The risks, costs, and benefits of possible future global policies for managing polioviruses
Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL
Am J Public Health, 2008; 98(7):1322-30. doi:10.2105/AJPH.2007.122192.
Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management
Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM
Risk Anal, 2008; 28(4):855-76. doi:10.1111/j.1539-6924.2008.01078.x.
Eradication versus control for poliomyelitis: an economic analysis
Thompson KM, Duintjer Tebbens RJ
Lancet, 2007; 369(9570):1363-1371. doi:10.1016/S0140-6736(07)60532-7.
Eradicating polio: the dollars and sense
Thompson KM
MedGenMed, 2007; 9(4):11.
Retrospective cost-effectiveness analyses for polio vaccination in the United States
Thompson KM, Duintjer Tebbens RJ
Risk Anal, 2006; 26(6):1423-40. doi:10.1111/j.1539-6924.2006.00831.x.
Body weight and water ingestion estimates for women in two communities in the Philippines: the importance of collecting site-specific data
Riederer AM, Thompson KM, Fuentes JM, Ford TE
Int J Hyg Environ Health, 2006; 209(1):69-80. doi:10.1016/j.ijheh.2005.08.002.
The costs of future polio risk management policies
Duintjer Tebbens RJ, Sangrujee N, Thompson KM
Risk Anal, 2006; 26(6):1507-31. doi:10.1111/j.1539-6924.2006.00842.x.
Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit
Wendler D, Belsky L, Thompson KM, Emanuel EJ
JAMA, 2005; 294(7):826-32. doi:10.1001/jama.294.7.826.
Value of information literature analysis: a review of applications in health risk management
Yokota F, Thompson KM
Med Decis Making, 2004; 24(3):287-98. doi:10.1177/0272989x04263157.
Integrated analysis: combining risk and economic assessments while preserving the separation of powers
Williams RA, Thompson KM
Risk Anal, 2004; 24(6):1613-23. doi:10.1111/j.0272-4332.2004.00554.x.
Estimation of tuberculosis risk on a commercial airliner
Ko G, Thompson KM, Nardell EA
Risk Anal, 2004; 24(2):379-88. doi:10.1111/j.0272-4332.2004.00439.x.
Validating benefit and cost estimates: the case of airbag regulation
Thompson KM, Segui-Gomez M, Graham JD
Risk Anal, 2002; 22(4):803-11. doi:10.1111/0272-4332.00070.
Genetic testing for lung cancer risk: if physicians can do it, should they?
Marcy TW, Stefanek M, Thompson KM
J Gen Intern Med, 2002; 17(12):946-51. doi:10.1046/j.1525-1497.2002.20378.x.
Emerging issues in vaccine economics: perspectives from the USA
Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL
Expert Rev Vaccines, 2002; 1(4):433-42. doi:10.1586/14760584.1.4.433.
Estimation of tuberculosis risk and incidence under upper room ultraviolet germicidal irradiation in a waiting room in a hypothetical scenario
Ko G, Burge HA, Nardell EA, Thompson KM
Risk Anal, 2001; 21(4):657-73. doi:10.1111/0272-4332.214142.
A dynamic programming approach to the efficient design of clinical trials
Claxton K, Thompson KM
J Health Econ, 2001; 20(5):797-822. doi:10.1016/S0167-6296(01)00093-5.
A scientific evaluation of health effects of two plasticizers used in medical devices and toys: A Report from the American Council on Science and Health
Koop CE, Juberg DR, Benedek EP, Brecher RW, Brent RL, Cole P, Corn M, Covello VV, Downes TW, Gad SC, Gold LS, Guengerich FP, Higginson J, Konemann WH, Lamb IJ, Lioy PJ, Lundberg GD, Thompson KM
MedGenMed, 1999:E14.
The cost-effectiveness of air bags by seating position
Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC
JAMA, 1997; 278(17):1418-25. doi:10.1001/jama.1997.03550170048031.